Aurobindo Pharma rallies nearly 3% on USFDA nod for hypertension drug

NEW DELHI: Aurobindo Pharma Ltd rallied as much as 2.7 per cent in trade on Wednesday after the pharma major said that it has received final approval from US health regulator to sell generic copies of Valsartan tablets used for treatment of hypertension.

At 09:40 a.m.; Aurobindo Pharma was trading 1.7 per cent higher at Rs 1107. It hit a low of Rs 1102.20 and a high of Rs 1118.50 in trade today.

The current annualised US market size for Valsartan tablets USP, 40 mg, 80 mg, 160 mg, and 320 mg as per IMS is around USD 2 billion, said the pharma firm.

Apart from Aurobindo Pharma Lupin and Jubilant Life Sciences have also received final approval from USFDA to sell generic copies of Valsartan tablets. Aurobindo Pharma says that the product is ready for launch, PTI reported.